Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05496296 · ClinicalTrials.gov registry record · NA
Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries
A NA study of Pressure Ulcer, Stage IV and Pressure Ulcers Stage II, sponsored by ULURU.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 14
- Study locations
NCT05496296 is a NA study of Pressure Ulcer, Stage IV and Pressure Ulcers Stage II that is actively recruiting participants, run by ULURU. The registered enrollment target is 300 participants. The trial reports 14 study locations across 8 states.
The verdict
NCT05496296, a NA study of Pressure Ulcer, Stage IV and Pressure Ulcers Stage II, is actively recruiting participants, sponsored by ULURU.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 14
- Study locations
Study Summary
Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin to full thickness wounds with deep tissue loss and exposed bone. This study will compare current standard of care treatment (as recommended by the National Pressure Injury Advisory Panel) to treatment with Altrazeal® in patients with stage 2, stage 3 and stage 4 pressure injury wounds. Altrazeal® is a Class 1, 501(k) exempt medical device listed with the FDA as a "dressing, wound, hydrogel" and has an extended wear time of up to 30 days. Subjects can be enrolled in the study either as an outpatient, or while hospitalized. Half of the subjects will be randomized to standard of care treatment, and the other half will be randomized to Altrazeal®. There are a total of up to 12 study visits taking place over 12 weeks.
Conditions Studied
Interventions
- DEVICE Altrazeal® Transforming Powder Dressing
Study Locations (14)
New York
- Northwell Health System/Zucker School of Medicine - Lake Success
- NYU Langone Hospital-Long Island - Mineola
- James J. Peters VA Medical Center - The Bronx
- Westchester Medical Center, 100 Woods, Road, Taylor Care Pavillion - Valhalla
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
- MedStar National Rehabilitation Hospital - Washington D.C.
Maryland
- Medstar Franklin Square Medical Center - Baltimore
- Medstar Good Samaritan Hospital - Baltimore
Texas
- VA North Texas Healthcare System - Dallas
- Michael E. DeBakey Houston VAMC - Houston
California
- San Diego VA - San Diego
Illinois
- Northwestern Medicine - Chicago
New Jersey
- Rutgers New Jersey Medical School, Ambulatory Care Center-Wound Care Clinic - Newark
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Presbyterian - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-04-30 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05496296
The ClinicalTrials.gov registry entry for NCT05496296 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ULURU, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pressure Ulcer, Stage IV appearing as the primary indexed condition, and to 1 intervention - of which Altrazeal® Transforming Powder Dressing is the first listed.
NCT05496296 reports 14 study locations spanning 8 distinct geographic areas - top geographies include New York, District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT05496296 about?
NCT05496296 is a clinical study titled "Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries". Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin to full thickness wounds with deep tissue loss and exposed bone. This study will compare current standard of care ...
What is the current status of trial NCT05496296?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2023-04-30. Estimated completion is 2026-12.
What conditions does trial NCT05496296 study?
This clinical trial studies the following conditions: Pressure Ulcer, Stage IV, Pressure Ulcers Stage II, Pressure Ulcers Stage III.
What interventions are being tested in trial NCT05496296?
The interventions under investigation include: Altrazeal® Transforming Powder Dressing (DEVICE).
Who is sponsoring clinical trial NCT05496296?
This trial is sponsored by ULURU, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05496296 being conducted?
This trial has 14 study locations across California, District of Columbia, Illinois, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pressure Ulcer, Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.